Absorption differences for sildenafil can be represented as differences in the upstream and early-stage geometry of systemic drug input. The sequence begins with solid-form disintegration and dissolution, continues through gastric emptying and delivery into the absorptive environment, and then produces an absorption rate and extent that shape the plasma concentration-time profile. In a mechanistic PK comparison, these processes are separated from downstream distribution, metabolism, clearance, and pharmacodynamic interpretation. Dissolution determines how rapidly drug material becomes available from the dosage form, while gastric emptying determines when that available material reaches the principal absorptive environment. Absorption rate then controls the geometry of the rising concentration phase, including how quickly concentrations increase and how the balance between input and elimination evolves before the peak. Absorption extent describes the total fraction entering systemic circulation and therefore contributes to overall exposure magnitude. Differences between sildenafil formulations or related products can therefore be described through input functions rather than subjective timing outcomes. The comparison is concerned with measurable PK parameters and their temporal relationships. This mechanistic framework distinguishes absorption geometry from later distribution and elimination processes. For a broader formulation-level comparison, see viagra vs sildenafil.
Dissolution and disintegration form the solid-phase portion of the absorption pathway. Disintegration describes physical breakup of a tablet or solid dosage form into smaller particles, increasing exposed surface area and allowing surrounding fluid to contact a greater fraction of the material. Dissolution is the subsequent conversion of drug from the solid state into a dissolved form that can participate in gastrointestinal transport and absorption. These processes are related but not identical: rapid disintegration can increase available surface area without necessarily producing instantaneous dissolution, while dissolution kinetics depend on physicochemical properties of the drug, particle characteristics, formulation structure, and excipient environment. Excipients can alter wetting, particle dispersion, matrix behavior, and the rate at which dissolved molecules become available. Mechanistically, the important consequence is the shape of the input function entering later absorption steps. A faster availability process can concentrate more systemic input into an earlier time interval, whereas slower availability can spread the same nominal input over a longer interval. This changes the ascending concentration curve without requiring a change in the total amount ultimately absorbed. Conversely, differences in dissolution can also alter absorption extent when incomplete dissolution limits the amount available for uptake. The distinction between rate and extent is therefore essential when interpreting formulation-dependent PK differences. These concepts fit within the broader framework described in pk comparison.
Gastric emptying determines the timing with which dissolved or dissolving drug material leaves the stomach and reaches the principal absorptive environment of the small intestine. In mechanistic terms, gastric emptying functions as a temporal transfer step between formulation disintegration and dissolution and the subsequent intestinal absorption process. The resulting input function depends on how material is released into the intestine over time. If gastric transfer is concentrated into an earlier interval, intestinal exposure to dissolved drug can begin earlier and the systemic concentration curve may acquire a steeper initial rising phase. If transfer is distributed over a longer interval, intestinal delivery can become more temporally dispersed, producing a broader or less steep input profile. Gastric emptying therefore interacts with dissolution rather than acting as an isolated determinant. Drug that has not yet dissolved may behave differently from drug already present in solution when it enters the intestine. The combined sequence of disintegration, dissolution, gastric transfer, and intestinal uptake determines the temporal geometry of systemic entry. Mechanistic absorption comparisons can consequently distinguish changes originating from the solid phase from changes arising from delivery timing. The resulting differences are expressed in PK variables such as the early concentration slope and Tmax rather than as subjective clinical timing. This relationship is further developed in onset comparison.
Absorption rate describes how rapidly drug crosses from the gastrointestinal environment into systemic circulation and is expressed through the geometry of the ascending concentration-time phase. A relatively concentrated absorption input produces a steeper early rise when systemic elimination is initially smaller than the incoming flux. A more dispersed input produces a shallower rise because systemic entry is distributed across a broader interval. The observed concentration trajectory is therefore a net result of absorption input and simultaneous disposition processes rather than a direct measurement of absorption alone. As absorption proceeds, the concentration rises until the rate of systemic input becomes balanced by distribution and elimination processes sufficiently for the profile to reach its maximum. Tmax is consequently a derived temporal feature of the complete concentration-time curve, not an isolated property of absorption. Changes in absorption rate can shift Tmax by altering the timing and steepness of the rising phase, while changes in elimination or distribution can also modify the point at which the peak occurs. Two profiles can therefore have similar exposure while displaying different rising-phase geometry and different Tmax values. Mechanistic interpretation requires separating these components rather than equating an earlier peak with a universally faster absorption process. The specific relationship between rising-phase input and peak timing is summarized in tmax.
Absorption extent describes how much of the administered drug input ultimately reaches systemic circulation, distinguishing the magnitude of systemic entry from the rate at which that entry occurs. A greater absorption extent increases the amount of drug contributing to systemic exposure, while a smaller extent reduces total systemic input. In PK terms, this distinction is closely connected to AUC because AUC integrates concentration over time and therefore reflects the cumulative systemic exposure produced by the combined input and disposition processes. Absorption extent does not, however, uniquely determine the shape of the early concentration curve. Two input functions can have similar total extent while differing substantially in temporal distribution, producing different rising-phase slopes and Tmax values. Conversely, an increase in total systemic input can alter peak concentration when the timing and disposition characteristics remain sufficiently similar, but Cmax is also influenced by absorption rate, distribution, and elimination. Thus, absorption extent and absorption rate represent separate dimensions of input geometry. Extent describes the integrated magnitude of systemic entry, whereas rate describes how that entry is distributed across time. Mechanistic comparison of these dimensions prevents AUC, Cmax, and Tmax from being treated as interchangeable descriptors. The relationship between systemic availability and cumulative exposure is further represented through bioavailability.
Onset variability can be defined mechanistically as variability in the formation of the early rising-phase PK profile. It does not refer to variability in a clinical outcome or subjective onset experience. Differences in solid-phase disintegration, dissolution kinetics, gastric emptying, intestinal delivery, and absorption rate can shift the timing and steepness of systemic concentration formation. If these upstream processes vary between otherwise comparable input conditions, the resulting concentration-time curves may display different early slopes, different Tmax values, or different temporal alignment even when later exposure characteristics are similar. Distribution can add another layer of early-profile variability because newly absorbed drug does not necessarily remain confined to plasma; movement between central and peripheral compartments can alter the measured plasma trajectory during the rising phase. Consequently, an observed early concentration difference cannot automatically be assigned to absorption alone. Mechanistic analysis separates input variability from distribution and elimination variability and evaluates how each component changes the concentration-time geometry. This framework also distinguishes variability in the rate of systemic entry from variability in the total extent of systemic exposure. The overall concept is therefore a PK variability problem involving multiple linked processes rather than a clinical onset construct. A broader treatment of these sources appears in pk variability.
Dissolution represents the conversion of sildenafil from its solid state into dissolved molecular form, making drug material available for subsequent gastrointestinal transport and absorption. Before dissolution can proceed efficiently, a solid dosage form may undergo disintegration, in which the larger structure breaks into smaller particles. Disintegration increases the surface area exposed to gastrointestinal fluid and can therefore modify the effective rate of dissolution. The relationship is kinetic rather than simply sequential: particle size, wetting, formulation structure, solid-state characteristics, and excipients can influence how quickly dissolved material becomes available. A change in dissolution rate can reshape the systemic input function by changing the amount of drug available to absorptive surfaces during each time interval. When dissolution is relatively rapid, a larger fraction of potentially absorbable material may become available earlier, concentrating input into the initial absorption phase. When dissolution is slower, input can become temporally dispersed. Dissolution rate and dissolution extent should nevertheless be separated. A slower rate does not inherently imply lower total systemic input if sufficient drug eventually dissolves and becomes absorbed. Conversely, incomplete dissolution can reduce the amount available for absorption and therefore affect total systemic exposure. Mechanistic comparison consequently treats dissolution as an upstream determinant of both temporal input geometry and, when limiting, absorption extent. This distinction is central to pk comparison.
Disintegration describes the physical breakup of a solid dosage form before or during dissolution and provides the surface-area transition that allows gastrointestinal fluid to interact more extensively with the drug material. A compact tablet presents a different effective surface area from the dispersed particles produced after breakup. Increasing exposed surface area can accelerate wetting and dissolution by shortening diffusion distances and increasing the interface between solid material and surrounding fluid. Excipients can influence this process through binding, swelling, porosity, lubrication, wetting, and matrix characteristics, creating formulation-dependent differences in the timing of available dissolved drug. The mechanistic consequence is not a direct clinical effect but a change in the upstream input function that feeds absorption. If two formulations contain equivalent active drug but differ in disintegration behavior, their subsequent dissolution curves can differ even before gastric emptying and intestinal absorption are considered. A faster disintegration process can therefore contribute to earlier availability without necessarily changing the eventual amount dissolved. Conversely, prolonged or incomplete disintegration can distribute availability over a longer interval. The distinction matters because the plasma concentration-time profile integrates these upstream events with gastric transfer, absorption, distribution, and elimination. Disintegration is consequently best viewed as an initiating physical determinant of absorption geometry rather than as a standalone PK endpoint. Its formulation context can be considered through viagra vs sildenafil.
| Absorption Domain | Mechanistic Determinant | Link |
|---|---|---|
| Dissolution | Initial availability for absorption. | pk comparison |
| Disintegration | Surface-area expansion. | viagra vs sildenafil |
Gastric emptying is a temporal transfer process that determines when drug material moves from the stomach into the intestinal environment where substantial absorption can occur. Its mechanistic importance arises from the fact that dissolution and absorption are time-dependent processes. Drug that remains in the stomach is separated temporally from the absorptive surface, whereas material delivered to the intestine becomes available for the next stage of systemic entry. The gastric emptying profile can therefore be represented as an input-transfer function describing how much material reaches the intestine during each interval. A concentrated transfer profile can produce an earlier and more concentrated intestinal input, while a dispersed transfer profile can spread available drug over a longer period. The effect of emptying is also coupled to dissolution. If material reaches the intestine predominantly in dissolved form, its availability for absorption differs from material that still requires dissolution after transfer. The resulting systemic concentration curve reflects the combined effects of formulation breakup, dissolution, gastric transfer, intestinal absorption, and concurrent disposition. Gastric emptying should therefore not be equated directly with absorption rate; it is an upstream determinant that can constrain when absorption begins and how input is distributed over time. Differences in this transfer process can shift the rising-phase geometry and contribute to differences in Tmax. The temporal relationship is represented conceptually in onset comparison.
Emptying variability represents differences in the timing and temporal distribution of gastric transfer that can alter the early systemic input profile. The relevant mechanism is variation in how rapidly and how continuously material moves from the stomach into the intestinal absorptive environment. A shorter transfer interval can concentrate intestinal delivery into a narrower time region, whereas a longer or more dispersed interval can distribute delivery across a broader region. These differences can interact with dissolution kinetics because the physical state of the material arriving in the intestine affects how quickly it can contribute to systemic absorption. Emptying variability therefore does not necessarily produce a proportional change in total absorption extent. It can primarily modify the timing of input and consequently the slope and curvature of the rising concentration phase. The resulting Tmax can shift because the peak occurs when the evolving input and disposition processes produce the maximum observed concentration. Early distribution can further modify the plasma trajectory after drug enters systemic circulation, making the measured concentration profile a combined representation of absorption and disposition. Mechanistic interpretation therefore treats gastric-emptying variability as one contributor among several sources of early PK variability. It is useful to separate this source from dissolution variability, intrinsic absorption-rate variability, and downstream distribution variability. These distinctions are part of the broader framework of pk variability.
| Emptying Domain | Mechanistic Determinant | Link |
|---|---|---|
| Gastric Emptying | Timing of systemic entry. | onset comparison |
| Emptying Variability | Timing variability. | pk variability |
Absorption rate describes the temporal intensity of systemic drug entry and is represented mechanistically by the shape of the rising concentration-time phase. When absorption input increases rapidly over a short interval, plasma concentration can rise steeply because systemic input temporarily exceeds the combined removal processes acting on the circulating drug. When absorption is distributed over a longer interval, the rising phase can become flatter and broader. The observed slope is therefore not a pure measurement of gastrointestinal transport because distribution and elimination operate concurrently. Nevertheless, absorption rate remains a major determinant of early concentration formation. A rate constant or other input parameter can describe the speed with which drug moves from an absorption compartment into the systemic compartment, while the full input function can capture more complex temporal patterns. Differences in rate can alter the point at which the concentration-time curve reaches its maximum, but the relationship is not one-to-one because Tmax also depends on disposition parameters. A faster input process generally compresses systemic entry into an earlier interval, whereas slower input can extend the rising phase. These changes can occur without requiring a proportional change in total absorption extent. Thus, absorption rate should be interpreted as a temporal property of input geometry, distinct from cumulative exposure. The resulting peak-timing relationship is developed through tmax.
The relationship between absorption rate and Tmax arises from the balance between systemic input and drug loss from the observed compartment. Tmax occurs at the point where the concentration-time curve changes from increasing to decreasing, meaning that the instantaneous processes producing concentration are no longer sufficient to maintain a positive slope. Absorption rate influences this transition because a rapid input phase can cause concentrations to rise quickly and reach the balance point earlier, whereas a slower input phase can prolong the ascending portion. However, Tmax is not determined by absorption rate alone. Distribution between compartments, metabolic elimination, renal elimination, and the shape of the absorption function can all influence when the maximum occurs. For this reason, two PK profiles with similar Tmax values may have different underlying absorption-rate characteristics, while two profiles with similar absorption rates can display different peak times if disposition differs. Tmax is consequently a summary parameter generated by the complete concentration-time trajectory rather than a direct assay of the absorption process. Mechanistic interpretation focuses on how changes in input geometry alter the location of the maximum while preserving the distinction between rate and extent. This prevents Tmax from being treated as synonymous with absorption rate. The peak-timing construct is represented in tmax.
| Rate Domain | Mechanistic Determinant | Link |
|---|---|---|
| Absorption Rate | Rising-phase steepness. | absorption |
| Rate → Tmax | Peak-timing formation. | tmax |
Absorption extent describes the cumulative amount of drug that successfully enters systemic circulation from the available gastrointestinal input. It is therefore a magnitude dimension of PK input rather than a timing dimension. When absorption extent increases while the temporal shape of input remains otherwise comparable, the integrated systemic exposure can increase, contributing to a larger AUC. A lower extent produces the opposite change in cumulative exposure. The relationship between absorption extent and AUC is nevertheless mediated by systemic disposition because AUC represents the time integral of plasma concentration after accounting for the complete input and elimination system. Absorption extent should therefore be distinguished from absorption rate. Two absorption functions may have the same total area, representing similar cumulative systemic input, while differing substantially in their timing. One can be concentrated early and the other distributed later, producing different rising-phase slopes and Tmax values despite similar integrated exposure. Conversely, two profiles with similar absorption rates can have different AUC values when their total systemic input differs. This rate-versus-extent distinction is fundamental to mechanistic bioavailability analysis. It allows formulation differences to be represented as changes in either the temporal distribution of input, the total amount entering systemic circulation, or both. Absorption extent is consequently a quantitative bridge between gastrointestinal availability and cumulative systemic exposure, as described in bioavailability.
Absorption extent can also influence Cmax because a greater total systemic input can provide more drug to the central compartment during the rising phase. However, the relationship between extent and peak magnitude is not equivalent to a direct proportionality in every PK configuration. Cmax depends on how much drug enters systemic circulation, how rapidly it enters, how distribution proceeds, and how rapidly drug is removed. If total extent changes while absorption rate and disposition remain otherwise comparable, peak concentration can shift because more drug contributes to the circulating concentration. If the same extent is delivered more rapidly, Cmax can also increase even without a change in cumulative systemic input. This demonstrates why Cmax combines information from both rate and extent. A high peak can arise from concentrated input, greater total input, altered distribution, or combinations of these factors. Mechanistic analysis therefore treats absorption extent as one determinant of Cmax rather than as its sole cause. The temporal separation between AUC, Cmax, and Tmax is important: AUC primarily captures cumulative exposure, Cmax summarizes maximum concentration, and Tmax identifies the time at which that maximum occurs. These parameters describe different geometrical properties of the same concentration-time system. The peak-magnitude relationship is developed further in cmax.
| Extent Domain | Mechanistic Determinant | Link |
|---|---|---|
| Absorption Extent | Exposure magnitude. | bioavailability |
| Extent → Cmax | Peak magnitude. | cmax |
Dissolution variability represents differences in the rate or completeness with which solid drug becomes dissolved and available for absorption. Mechanistically, variability can arise from differences in particle characteristics, solid-state properties, wetting behavior, formulation structure, and the interaction of excipients with gastrointestinal fluid. When dissolution is rate-limiting, small changes in the dissolution process can redistribute systemic input across time. A faster dissolution trajectory can make a greater proportion of absorbable material available during the early input phase, whereas a slower trajectory can spread availability across a longer interval. If total dissolution remains complete, the primary consequence may be a change in timing rather than cumulative systemic input. If dissolution is incomplete, the extent of available drug can also change. The early plasma concentration profile consequently reflects the combined geometry of dissolution and downstream absorption rather than dissolution in isolation. Variability in this upstream step can produce differences in the slope, curvature, and temporal alignment of the rising concentration phase. Such changes are appropriately described as PK onset variability because they concern the formation of the early systemic concentration trajectory. They do not constitute a statement about clinical onset or subjective response. Mechanistic analysis separates dissolution variability from gastric-emptying variability because one concerns solid-to-dissolved availability while the other concerns gastrointestinal transfer timing. Both can influence the same observed concentration-time region through different pathways. The broader framework is covered in pk variability.
Emptying variability concerns differences in the timing and distribution of gastric transfer into the intestinal environment. Because gastric emptying determines when available drug reaches the primary absorptive surface, changes in the emptying profile can shift the timing of intestinal exposure and consequently the timing of systemic input. A relatively concentrated emptying event can generate a more temporally focused intestinal input, whereas prolonged emptying can distribute delivery over a wider interval. The effect on plasma concentration depends on the state of the drug at the time of transfer, because undissolved material continues to undergo dissolution after reaching the intestine while already dissolved material can participate in absorption more directly. Emptying therefore interacts with dissolution rather than functioning as an independent switch. Variability in emptying can change the rising-phase slope and the location of Tmax without necessarily changing total absorption extent. The resulting differences are temporal properties of PK geometry. If emptying is one of several variable processes, its contribution can be separated conceptually from dissolution rate, intestinal absorption kinetics, distribution, and elimination. This decomposition is important because the same observed shift in an early concentration curve can arise from different mechanistic causes. A PK model can represent emptying as an upstream transfer function whose variability changes the timing of downstream input. Such variability belongs to the broader category of early-profile PK variability rather than clinical onset variability. The relevant framework is summarized in pk variability.
Rate and distribution variability affect different stages of the early systemic concentration trajectory. Absorption-rate variability changes how quickly drug enters systemic circulation, modifying the steepness, curvature, and temporal width of the rising phase. A faster input function can concentrate systemic entry into an earlier interval, whereas a slower function can produce a more gradual rise. Distribution variability acts after systemic entry and describes differences in how rapidly drug moves between circulating and peripheral compartments. Because plasma concentration is measured within one compartment of this dynamic system, early distribution can alter the observed concentration trajectory even when the gastrointestinal input function is unchanged. A rapid distribution phase can temporarily reduce central concentration relative to a model with slower distribution, while redistribution can subsequently return drug to the central compartment. These processes can therefore influence the apparent geometry surrounding Tmax and the early decline without representing changes in absorption itself. Mechanistic decomposition is consequently essential: variability in rising-phase formation may originate upstream from dissolution and emptying, within absorption kinetics, or downstream from distribution. The term onset variability in this context refers only to variability in the timing and shape of early PK concentration formation. It does not imply variability in clinical response. The distinction between absorption and distribution processes is further represented through distribution.
| Variability Domain | Mechanistic Determinant | Link |
|---|---|---|
| Dissolution Variability | Availability variability. | pk variability |
| Emptying Variability | Timing variability. | pk variability |
| Rate Variability | Rising-phase variability. | pk variability |
| Distribution Variability | Equilibration variability. | distribution |
In mechanistic pharmacokinetics, absorption is the process through which drug molecules move from the site of administration into the systemic circulation. For an orally administered solid formulation, it is not a single event. The pathway can include disintegration of the solid dosage form, dissolution into gastrointestinal fluid, gastric transfer, intestinal availability, membrane transport, and entry into the circulating compartment. Absorption therefore has both rate and extent dimensions. Absorption rate describes how systemic entry is distributed over time and shapes the rising phase of the plasma concentration-time curve. Absorption extent describes the cumulative amount that reaches systemic circulation and contributes to overall exposure. These dimensions can change independently: the same total amount can enter over different time intervals, or different amounts can enter with similar temporal patterns. In PK analysis, absorption is distinguished from distribution, metabolism, and elimination because those processes occur after or alongside systemic entry and contribute separately to concentration-time geometry.
Disintegration and dissolution are upstream processes that determine how quickly solid drug becomes available for absorption. Disintegration breaks a solid dosage form into smaller particles, increasing the surface area exposed to gastrointestinal fluid. Dissolution then converts drug from the solid state into dissolved molecular form. The rate of these processes can influence the timing of the downstream absorption input. Faster disintegration may expose more surface area and facilitate faster dissolution, while slower disintegration can distribute dissolution over a longer interval. Formulation characteristics and excipients can modify wetting, particle dispersion, matrix behavior, and dissolution kinetics. These processes primarily influence input geometry when the total amount eventually dissolved remains similar. If dissolution is incomplete, they can also influence absorption extent by limiting the amount available for systemic entry. Consequently, differences in disintegration or dissolution can alter the timing, slope, and width of the rising plasma concentration phase without necessarily changing the total systemic input. They are therefore mechanistic determinants of absorption rather than direct measures of clinical timing.
Gastric emptying shapes absorption geometry by controlling the timing with which drug material moves from the stomach into the intestinal environment. Because substantial absorption occurs after intestinal delivery, the emptying process acts as a temporal transfer function between gastric formulation behavior and systemic input. Earlier or more concentrated transfer can place available drug into the absorptive environment within a narrower time interval, potentially producing a more concentrated downstream input. More prolonged transfer can spread intestinal delivery across time and broaden the absorption input function. The effect depends on the physical state of the drug because dissolved material and undissolved particles follow different subsequent processes. Gastric emptying therefore interacts with dissolution rather than simply determining absorption on its own. Variability in emptying can shift the rising-phase concentration geometry and contribute to differences in Tmax. Importantly, this interpretation concerns PK formation only. In this framework, onset geometry means the timing and shape of early systemic concentration formation, not a subjective or clinical onset event. Emptying is one upstream determinant among several that contribute to the observed plasma profile.
Absorption rate determines how rapidly drug enters systemic circulation and therefore strongly influences the geometry of the rising concentration phase. A concentrated absorption input can generate a steeper increase in plasma concentration, whereas a more distributed input can produce a broader and shallower rise. Tmax is the time at which the observed concentration reaches its maximum, so changes in absorption rate can shift the location of that maximum. The relationship is not exclusive, however, because Tmax also reflects distribution and elimination processes occurring simultaneously with absorption. A rapid absorption process can move the balance between input and drug loss earlier, while slower absorption can prolong the ascending phase. Two profiles can therefore have different absorption rates and similar Tmax values if other PK parameters differ, or similar absorption rates and different Tmax values if disposition differs. Tmax is consequently a summary feature of the complete concentration-time curve rather than a direct measurement of absorption rate. Mechanistically, rate describes temporal input geometry, while Tmax describes the resulting peak location after absorption and disposition interact.
Absorption extent describes the cumulative amount of drug that enters systemic circulation from the available gastrointestinal input. Greater extent generally increases the amount contributing to systemic exposure, while lower extent reduces cumulative systemic input. Because AUC represents the integrated concentration-time profile, absorption extent is closely related to exposure magnitude when systemic disposition is appropriately accounted for. Extent should nevertheless be separated from absorption rate. Two absorption processes can deliver the same total systemic amount while distributing that amount differently across time. One may generate a concentrated early input and the other a prolonged input, producing different Cmax and Tmax values despite similar cumulative exposure. Conversely, a change in total systemic input can alter Cmax even when the temporal input pattern remains similar. Cmax therefore reflects both the amount entering the system and how rapidly it enters, along with distribution and elimination. Absorption extent is best understood as the magnitude dimension of systemic input, whereas absorption rate is its temporal dimension. This distinction allows AUC, Cmax, and Tmax to be interpreted as separate properties of the same PK concentration-time system.
In a mechanistic PK framework, onset variability refers to variability in the timing and shape of the early rising plasma concentration profile. Several processes can contribute. Differences in disintegration and dissolution can change how rapidly drug becomes available for absorption. Differences in gastric emptying can shift when available material reaches the intestinal absorptive environment. Differences in absorption kinetics can change the steepness and duration of the rising phase. Distribution after systemic entry can also modify the observed plasma trajectory because drug can move between central and peripheral compartments while absorption is still occurring. These mechanisms can produce variation in early concentration slope, curvature, and Tmax even when later exposure characteristics are similar. Variability in absorption extent represents a different dimension because it changes cumulative systemic input rather than solely its timing. Mechanistic analysis therefore separates dissolution, emptying, absorption rate, absorption extent, distribution, and elimination instead of assigning every early-profile difference to one process. The term onset variability in this context does not describe clinical response variability; it specifically describes variability in early PK concentration formation and temporal alignment.